AI-Native Scoping Reviews & Evidence Mapping

Gastric ESD is not simply a technical alternative to surgery — this review shows where it truly works, where it becomes risky, and which anatomical settings demand expert-level planning. The full read maps 330 references across early gastric cancer, remnant stomach, gastric tube lesions, bleeding risk, perforation, traction methods, novel injection materials, training pathways, and surveillance to clarify one practical message: ESD success depends less on feasibility than on correct lesion selection, procedural difficulty control, and long-term metachronous cancer surveillance.

TEndurant is not just another EVAR device story: this review shows where its long-term durability is real, and where it becomes fragile. The full read maps registry, hostile-neck, chimney, EndoAnchor, limb, renal, and late endoleak evidence to clarify a practical point for vascular specialists: Endurant success is driven less by deployability and more by proximal sealing quality, anatomy, and surveillance.

Erectile dysfunction is often treated as a private urological complaint, but this review shows why it may be an early vascular warning signal. The full read maps more than 800 original studies to clarify how vasculogenic ED overlaps with cardiovascular risk, subclinical atherosclerosis, diabetes, hypertension, PDE5 inhibitor safety, and the need for integrated urology–cardiology care.

Flow diverters have reshaped aneurysm treatment, but their success depends heavily on anatomy, device behavior, and procedural strategy. The full read maps 252 references and 1439 original studies to separate strong indications from high-risk zones, giving a practical evidence overview for clinicians, researchers, and endovascular teams.

Stent retrievers are no longer just a device story; this review shows them as a full procedural ecosystem where aspiration strategy, device sizing, balloon-guide support, clot biology, and first-pass optimization shape real clinical success. The full read is valuable because it separates where stent-retriever thrombectomy is firmly evidence-based from where practice is still driven by anatomy, technique, emerging devices, and lower-certainty frontier applications.

Viabahn is not one device story but a whole vascular strategy: emergency bleeding control, femoropopliteal reconstruction, dialysis-access salvage, aneurysm exclusion, and complex aortic bridging all appear in the evidence map. The full review separates where Viabahn and VBX look durable from where patency depends heavily on anatomy, sizing, runoff, mobility zones, and antiplatelet planning.

Supera is not just another femoropopliteal stent story: the evidence shows a device whose success depends heavily on deployment precision, vessel preparation, lesion mechanics, and anatomical stress. The full review separates durable patency signals from real-world failure zones, including elongation, fracture, popliteal stress, dialysis-access uncertainty, and off-label use beyond the core femoropopliteal indication.

PCSK9 base editing is moving from experimental promise toward clinical reality, with single-dose therapies already producing durable LDL-C reductions in both primates and early human studies. The full evidence map reveals which delivery platforms, editing strategies, and safety signals are driving this transition—and where the remaining uncertainties still lie.

Surgery does not end when the operation ends: this review shows that across oncology, bariatrics, orthopedics, transplantation, and vascular care, postoperative medication adherence is often the hidden determinant of recurrence, complications, and survival. The full read is worth it because it separates where adherence reliably fails, which barriers drive that failure, and which interventions actually help keep patients on treatment after discharge.